> Nymox Pharmaceutical is touting the long-term results of a clinical study for its benign prostatic hyperplasia therapy. Report
> Growing competition for the respiratory market hasn't fazed most analysts, who see GlaxoSmithKline as the dominant player in the field for years to come. Report
> Agency staffers have raised questions over the need to approve Novartis' Exelon as a therapy for mild to moderate dementia in patients with Alzheimer's. Article (Wall Street Journal sub. req.)
> Vectura Group and Unilever Ventures have spun out PharmaKodex to concentrate on developing new combinational therapies or finding new uses for existing drugs. Release
> DUSA announced that a federal court has issued an injunction blocking River's Edge Pharmaceuticals from marketing a generic version of Nicomide. Report
> The FDA has toughened the warnings on three asthma medications. Report
And Finally… The New England Journal of Medicine's handling of the Vioxx case has emerged as a cautionary tale that underscores just how important the medical journals' editorial independence can be. Article